(NASDAQ: MIRM) Mirum Pharmaceuticals's forecast annual revenue growth rate of 19.7% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 89.15%, and while it is forecast to beat the US market's average forecast revenue growth rate of 11.71%.
Mirum Pharmaceuticals's revenue in 2025 is $429,161,000.On average, 6 Wall Street analysts forecast MIRM's revenue for 2025 to be $25,567,847,589, with the lowest MIRM revenue forecast at $25,124,349,641, and the highest MIRM revenue forecast at $26,102,979,005. On average, 6 Wall Street analysts forecast MIRM's revenue for 2026 to be $31,295,692,912, with the lowest MIRM revenue forecast at $28,801,745,402, and the highest MIRM revenue forecast at $32,810,709,632.
In 2027, MIRM is forecast to generate $36,965,965,891 in revenue, with the lowest revenue forecast at $32,775,643,755 and the highest revenue forecast at $39,697,788,659.